Regentis Biomaterials Ltd. (RGNT) is a Herzliya, Israel–based regenerative medicine company focused on orthopedic tissue repair. Its lead product candidate, GelrinC, is a cell-free, off-the-shelf hydrogel implant that is injected as a liquid into a knee cartilage lesion and cured with UV light, then gradually resorbed as new tissue forms. GelrinC holds CE Mark approval in Europe and is being evaluated in a U.S. pivotal Phase III trial under an FDA investigational device exemption.
In Thursday's trading, the stock changed hands at $1.00, down $0.14, or 12.28%, from the previous session's close of $1.14. The direction was decisively lower, and the intraday print of $1.00 marked the weakest level since the company listed on the NYSE American at $8.00 per share in December 2025. No verified news or fundamental development was identified to explain the decline; the move instead reflects a continuation of a downtrend that has been in place for months.
No verified news or fundamental catalyst found to account for Thursday's drop. No press release, SEC filing, pricing announcement, regulatory update, or analyst rating change was published in the window leading into the move, and the company's most recent material disclosure remains its November 9 announcement of a four-year exclusive distribution agreement for GelrinC in Israel. That release lifted the shares at the time but has not produced follow-through buying.
The most plausible technical explanation is a liquidity vacuum layered on top of persistent selling pressure. Average daily volume over the past 20 sessions is roughly 47,000 shares, and the public float is only about 4.26 million shares — a combination that allows relatively small orders to move the quote meaningfully. Thursday's activity was not visibly heavy in the tape, which is consistent with a thin order book rather than institutional distribution. The stock has also traded below both its 50-day and 200-day moving averages, near $1.61 and $2.68 respectively, for weeks, keeping trend-following and momentum-driven flows on the sell side.
The company's disclosure cadence has been steady but incremental. First-half 2026 results, reported in mid-September, showed progress in the U.S. pivotal trial with enrollment targeted for completion around year-end 2026, alongside European commercialization readiness and a previously announced manufacturing process that lifts production yield by 400%. Each of those items was constructive but small relative to the scale of the company's cash needs, and none represented the kind of binary event — pivotal data or an FDA decision — that typically resets a micro-cap device story. Investors have also weighed the dilution history: shares outstanding rose sharply over the past year following a $6.5 million private placement and the IPO itself.
Volume on Thursday was not materially elevated relative to the roughly 46,000-share daily average, underscoring that a modest number of trades is enough to displace the price in a name this illiquid. The move was similarly not mirrored by broad indices or by large-cap orthopedic and medical-device peers, which is consistent with a company-specific repricing rather than a sector rotation or macro event. Technically, the session broke the prior 52-week low of $1.14 with little support underneath, and the $1.00 round number now becomes the reference level traders will monitor. The stock's softness places it roughly 87% below its IPO price and well under its 52-week high of $15.50.
The score is measured on a 0-to-100 scale, where 0 reflects no meaningful news and a routine price move, and 100 reflects transformative news paired with an extreme, rare move. Regentis earns 18 out of 100.
The news component is essentially absent: no verified catalyst existed on Thursday, leaving only technical and flow-driven pressure to explain the session. The price component is moderate. Thursday's 12.28% decline was about 3.6 times the stock's average absolute daily move of roughly 3.4% across the last 60 sessions, and a move of that size occurred only once in that stretch — the 23% gain on September 21. With volume unremarkable, the two components combine into a low overall score.
Attention now centers on trial execution. Management has guided toward completing enrollment in the U.S. pivotal study around year-end 2026, and any update on that timetable — or on the pace of European commercialization following the Israeli distribution agreement — is the most likely near-term inflection point. No quarterly earnings date has been confirmed for the current period, and analyst coverage remains thin, with limited published estimates to anchor expectations.
Key risks include the company's cash runway relative to the cost of finishing a pivotal device trial, the potential need for additional capital that could dilute existing holders, and the possibility of further delays in the regulatory process. Upside would depend on clean data and a credible path to U.S. approval; downside remains tied to financing conditions and the illiquidity that amplifies moves in both directions.
Tickeron's Trending AI Robots page highlights the automated trading strategies performing best under current market conditions. Tickeron offers hundreds of AI trading bots spanning thousands of tickers, but only the strongest performers earn a place in this curated section. Bots differ widely by strategy, timeframe, performance metrics, and the symbols they trade, so the page offers a practical starting point for comparing approaches. Investors researching names like Regentis can explore the featured robots to see how systematic strategies are positioned right now.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
The RSI Indicator for RGNT moved out of oversold territory on November 09, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 10 similar instances when the indicator left oversold territory. In 9 of the 10 cases the stock moved higher. This puts the odds of a move higher at 90%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for RGNT just turned positive on November 02, 2026. Looking at past instances where RGNT's MACD turned positive, the stock continued to rise in 5 of 6 cases over the following month. The odds of a continued upward trend are 83%.
Following a +11.77% 3-day Advance, the price is estimated to grow further. Considering data from situations where RGNT advanced for three days, in 18 of 26 cases, the price rose further within the following month. The odds of a continued upward trend are 69%.
RGNT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RGNT as a result. In 13 of 13 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RGNT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for RGNT entered a downward trend on November 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 37 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.088) is normal, around the industry mean (4.964). P/E Ratio (-0.050) is within average values for comparable stocks, (40.591). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (56.876).
The Tickeron Price Growth Rating for this company is 79 (best 1 - 100 worst), indicating slightly worse than average price growth. RGNT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RGNT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry PharmaceuticalsOther